Similarly, the HER2-targeted cohort had incremental breast cancer-specific costs of $2,307 (95% CI: $1,817–$2,796) and $3,357 (95% CI: $2,855–$3,859) compared to the no HER2-targeted cohort and the no treatment cohort, respectively. The gene discussed is ERBB2; the disease is breast cancer.